|
|
|
|
|
|
| ||||
Last Loaded on Web: Thursday, May 01, 2008
IMS Company Profiles examines annually the internal make-up of key pharmaceutical companies worldwide. Each profile analyzes the critical components that make up a pharmaceutical company, providing a clear assessment of the relative strengths and weaknesses of a company's business strategy.
Generic, biotechnology and drug delivery companies are profiled. They include national, multinational, public, and private firms.
File 449 is publicly available; File 984 is available only to subscribers of electronic or equivalent products from IMS.
USE FILE 449to find in-depth reports on key pharmaceutical companies. EXPAND MT=to get a list of companies profiled in the database. E MT=BRISTOLSEARCH SE=PROFILE UPDATESto review the additions and changes to a company profile. S CO=AMGEN? AND SE=PROFILE UPDATES
|
The key components covered in each profile include:
Also included are company updates, which are issued regularly as events of commercial significance occur. Each profile comprises several records, one or more for each section, which is indexed in the SE= field, e.g., SE=CORPORATE STRUCTURE and SE=STRATEGY STATEMENT.
IMS Health collects data for Company Profiles from interviews with top company executives and financial analysts, press conferences, and investor meetings, as well as IMS Health's own extensive in-house information services. Published sources consulted include annual reports, analysts' reports, newswires, and the trade press.
| Dates Covered: | 1995 to the present |
|---|---|
| File Size: | More than 60,000 records as of September 2006 |
| Update Frequency: | Monthly |
| ACRONYM | CATEGORY NAME |
|---|---|
| CODIR | Company Directories |
| DRUGPRO | Pharmaceutical Company Profiles |
| IMS | IMS Files |
| IMSSUB | IMSworld Subscriber Files |
| MERGEACQ | Mergers and Acquisitions |
|
IMS Company Profiles is produced by IMS Health. Questions concerning file content should be directed to: Customer Services Dept., Global Services, 7 Harewood Avenue London, NW1 6JB England
|
For Dialog's Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply.
These databases are copyrighted by IMSworld Publications. No part of these databases may be copied or duplicated in hard copy or machine-readable form without prior written permission of IMSworld Publications.
If data is to be distributed under Dialog's Redistribution policy, distribution is restricted to within the geographic boundaries of the country where the data was first downloaded. Under NO CIRCUMSTANCES may data which has been downloaded, distributed, or copied under this provision be sold or resold to a third party outside the user's company organization.
| File 449:IMS Company Profiles 1992-2002/Oct | |
| (c) 2002 IMS Health & Affiliates. All rts. reserv. | |
| 00003849 (THIS IS THE FULLTEXT) | |
| /TI, SE= | BRISTOL-MYERS SQUIBB: STRATEGY STATEMENT |
| /MT, MT= | Main Title: BRISTOL-MYERS SQUIBB |
| CS= | Source: IMSworld Publications, Ltd Telephone: +44 71 |
| 387 8434 | |
| PD=, PY= | January 1 1994 |
| LA=, RT= | Language: English Record Type: Fulltext |
| WD= | Word Count: 449 |
| /TX | In 1992, Bristol-Myers Squibb was the world`s number three drug |
| company, behind Merck (USA) and Glaxo (UK), according to IMS. It | |
| develops, manufactures and markets ethical drugs, medical | |
| devices, OTC healthcare products (including nutritionals), and | |
| consumer products. | |
| 1992 was not a good year for drug companies and Bristol-Myers | |
| Squibb was badly affected, with shares diving from $98 in early | |
| 1992 to $50 by the end of the year. Price rises only in line with | |
| inflation at 4%; reductions in wholesalers` inventories; and | |
| uncertainties about reimbursement policies in Europe and the | |
| situation in the US drug market all took their toll in 1992. BMS | |
| also had heavy marketing costs as a result of new drug launches: | |
| the antiviral Videx (didanosine) and the antibiotic Cefzil | |
| (cefprozil); the cardiovascular agents Pravachol (pravastatin) | |
| and Monopril (fosinopril); and the nasal spray analgesic Stadol | |
| NS. | |
| In October 1992, Bristol-Myers Squibb announced plans to reduce | |
| its workforce worldwide by 6% (2,200), from the first quarter of | |
| 1993. It also intends to consolidate some of its operations by | |
| closing down or shrinking 15 drug plants over the next two years. | |
| However, brokers consider that the company is still financially | |
| strong, although growth is likely to slow down considerably over | |
| the next few years. | |
| Further restructuring was announced in December 1993, when BMS | |
| announced moves which would result in the elimination of 5,000 | |
| jobs over the next two years. The company also announced that | |
| its US sales force would be organized into 12 regional business | |
| units "supported by a strengthened managed care operation and a | |
| marketing staff with a structure which reflects the changing | |
| status of health care buyers in the United States." | |
| In the current climate, analysts think major reorganization may | |
| be on the cards for Bristol-Myers Squibb. They have commented in | |
| the past that the consumer goods units were holding back profit | |
| growth: operating margins for consumer products are 17% while the | |
| rest of the company`s products average 28%. Some restructuring | |
| has already taken place: in 1992, Drackett, Bristol-Myers | |
| Squibb`s household product unit, was sold to SC Johnson Wax (USA) | |
| for $1.15 billion. Drackett had sales of $65 million in 1992. | |
| Copyright (c) 1994 IMSworld Publications, Ltd. All rights | |
| reserved. | |
| /CO, CO= | Company: BRISTOL-MYERS SQUIBB |
| SEARCH SUFFIX |
DISPLAY CODE |
FIELD NAME |
INDEXING |
SELECT EXAMPLES |
|---|---|---|---|---|
| None | None | All Basic Index Fields | Word | S ETHICAL(W)DRUGS |
| /CO | CO | Company Name1 | Word | S BRISTOL(W)MYERS(W)SQUIBB/CO |
| /MT | MT | Main Title1 | Word | S SQUIBB/MT |
| /TI | TI | Title | Word | S STRATEGY/TI |
| /TX | TX | Text | Word | S ETHICAL(W)DRUGS/TX |
1 Searchable in the Basic Index and in the Additional Indexes.
| SEARCH PREFIX |
DISPLAY CODE |
FIELD NAME |
INDEXING |
SELECT EXAMPLES |
|---|---|---|---|---|
| None | AA | DIALOG Accession Number | ||
| CO= | CO | Company Name1 | Phrase | S CO=BRISTOL-MYERS SQUIBB? |
| CS= | CS | Source of Data | Phrase | S CS=IMSWORLD? |
| LA= | LA | Language2 | Phrase | S LA=ENGLISH |
| MT= | MT | Main Title1 | Phrase | S MT=BRISTOL-MYERS SQUIBB? |
| PD= | PD | Publication Date | Phrase | S PD=940101 |
| PY= | PY | Publication Year | Phrase | S PY=1994 |
| RT= | RT | Record Type2 | Phrase | S RT=FULLTEXT |
| SE= | SE | Section Name | Phrase | S SE=STRATEGY STATEMENT |
| UD= | None | Update | Phrase | S UD=9999 |
| WD= | WD | Word Count3 | Numeric | S WD=400:500 |
2 All company profiles currently available are in English and are full-text records.
3 For searching, numeric entries are rounded down to the two left-most significant digits and zero-filled to the right. The actual word count displays in the record. Use numeric operators (>, <, >=, <=) to search a range of values, e.g., S WD>=450.
| Sets and terms can be restricted by Basic Index suffixes, i.e., /CO, /MT, /TI, /TX (e.g., S S2/TI), as well as by the following features: | ||
| SUFFIX | FIELD NAME | EXAMPLES |
|---|---|---|
| / | DIALOG Accession Number | S S3/001065-999999 |
| /ENG | English Language | S S1/ENG |
| /FULLTEXT | Full-text Records | S S4/FULLTEXT |
| /YYYY | Publication Year | S S2/1993 |
| SORTABLE FIELDS | EXAMPLES |
|---|---|
| CO, PD, PY, TI | SORT S13/ALL/PY,D PRINT S4/5/1-24/TI |
| RANK FIELDS | EXAMPLES |
|---|---|
| All phrase- and numeric-indexed fields in the Additional Indexes can be ranked. | RANK CO RANK SE S4 |
| Display codes listed in the Search Options tables can be used to customize output. | TYPE S3/TI,PD/1-5 |
| NO. |
DIALOGWEB FORMAT |
RECORD CONTENT |
|---|---|---|
| 1 | -- | DIALOG Accession Number |
| 2 | -- | Full Record except Text |
| 3 | Medium | Full Record except Text |
| 4 | -- | Full Record |
| 5 | -- | Full Record |
| 6 | -- | Title, Publication Date, and Word Count |
| 7 | Long | Full Record |
| 8 | Short | Title, Publication Date, and Word Count |
| 9 | Full | Full Record |
| K | -- | KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats |
| FIELD NAME | EXAMPLES | ||
|---|---|---|---|
| If the accession number of a specific record is known, it can be used to display the record directly. | TYPE 00003849/3 DISPLAY 00003849/TI,PD PRINT 00003849/9 |
||
Add RSS
Rates For File: IMS Company Profiles[449]
Cost per DialUnit: $17.00
Cost per minute: $2.97
Rank Elements $0.00
ALERT (default) $18.24
ALERT (Monthly) $18.24
ALERT (Biweekly/twice a month) * $18.24
ALERT (Weekly) * $18.24
ALERT (Daily) * $18.24
ALERT (Calendar weekly) * $18.24
ALERT (Intraday) * $18.24
* = custom scheduled Alerts only
ALERT Number of included prints 0
Format Types Prints
1 $0.00 $0.00
2 $0.00 $0.00
3 $0.00 $0.00
4 $32.88 $32.88
5 $32.88 $32.88
6 $0.28 $0.28
7 $32.88 $32.88
8 $0.28 $0.28
9 $32.88 $32.88
KWIC95 $1.37 NA
KWIC96 $1.32 NA
REDIST/COPY Multiplier Table:
Range Multiplier
1-2 1.00
3-25 1.50
26-100 3.00
101-200 4.00
201-500 6.00
501-1000 8.00
1001 or more 10.00
ARCHIVE Multiplier Table:
Range Multiplier
1-25 1.50
26-200 3.00
201-500 6.00
501-1000 8.00
1001 or more 10.00
Rates For File: IMS Company Profiles - subscribers[984]
Cost per DialUnit: $15.86
Cost per minute: $2.70
Report Elements $0.00
LOB Reports $0.00
SHARE Reports $0.00
CROSSTAB Report Records $0.00
Rank Elements $0.00
Format Types Prints
1 $0.00 $0.00
2 $0.27 $0.27
3 $0.27 $0.27
4 $9.08 $9.08
5 $9.08 $9.08
6 $0.27 $0.27
7 $9.08 $9.08
8 $0.27 $0.27
9 $9.08 $9.08
KWIC95 $0.92 NA
KWIC96 $0.92 NA
REDIST/COPY Multiplier Table:
Range Multiplier
1-2 1.00
3-25 1.50
26-100 3.00
101-200 4.00
201-500 6.00
501-1000 8.00
1001 or more 10.00
ARCHIVE Multiplier Table:
Range Multiplier
1-25 1.50
26-200 3.00
201-500 6.00
501-1000 8.00
1001 or more 10.00
